קורות חיים
שנת לידה: 1967
מצב משפחתי: נשוי + 2
השכלה:
2005- 2007 : מוסמך בניהול מערכות בריאות M.H.A, אוניברסיטת בן- גוריון
בנגב.
1997 - 2003: תואר דוקטור בפרמקולוגיה Ph.D.האוניברסיטה העברית, ירושלים.
1997-1994: תואר מוסמך ברוקחות M.Sc. Pharm., (בהצטיינות). ביה"ס לרוקחות, הפקולטה לרפואה, האוניברסיטה העברית, ירושלים.
1993-1989: תואר בוגר ברוקחות B.Pharm, ביה"ס לרוקחות, הפקולטה לרפואה, האוניברסיטה העברית, ירושלים.
1985-1982: תעודת בגרות מלאה, מגמה ביולוגית-ריאלית תיכון מקיף ע"ש רוטברג, רמת השרון.
נסיון מקצועי:
2002 - : ס. מנהל מערך רוקחות ראשית ופרמקולוגיה, חטיבת הבריאות, מכבי שירתי בריאות.
2000 – : מרצה אורח בבית הספר לרוקחות במסגרת לימודי תאר ראשון ברוקחות, המדור ללימודי המשך של ביה"ס לרוקחות והקורס לרוקחים עולים חדשים.
1998- 2002: רוקח מטה באגף הרוקחות ב"מכבי שירותי בריאות".
1998-1994: רוקח קהילתי, מכבי שירותי בריאות.
1994-1993: רוקח ביחידה לפרמקולוגיה קלינית ומידע תרופתי, המרכז הרפואי כרמל, חיפה.
1993: סטאג' בבית-מרקחת קהילתי, מכבי שירותי בריאות.
1990 – 1993: עוזר מחקר במעבדה לפרמקולוגיה, ביה"ס לרוקחות, הפקולטה לרפואה, האוניברסיטה העברית, ירושלים.
שירות צבאי:
2002- : קורס קציני חר"פ, (דרגת סגן במילואים)
1986-1989: שירות צבאי מלא
חברות בארגונים מקצועיים:
1996 – ארגון הרוקחות בישראל (חבר הועדה המקצועית משנת 2001, ס. יו"ר הארגון 2005- 2003)
1994 – האגודה הישראלית לרוקחות קלינית וביורוקחות
2005 – ASCPT - האגודה האמריקאית לפרמקולוגיה קלינית
2007 – ISPOR - האגודה הבין–לאומית והסניף הישראלי.
SCIENTIFIC PUBLICATIONS
1. J. Shani, Y. Milner, Y. Politi, I. Katzir, O. Chomski and S. Brener: Inhibition of psoriatic cell proliferation in tissue culture, by selected dead-sea salts. Pharmacol. Comm. 7:21-27(1995).
2. J. Shani, A. Suliman, I. Katzir, S. Brener: Penetration of selected dead sea minerals through a healthy rabbit skin, from a sustained-release transparent varnish, as a prospective treatment for psoriasis. J. Eur. Acad. Dermatol. Venereol. 4:267-272(1995).
3. J. Sela, J. Shani, D. Kohavi, W. A. Soskolne, I. Katzir, B. D. Boyan and Z. Schwartz: Uptake and biodistribution of 99mTechnetium methylene-[32P]diphosphonate during endosteal healing around titanium, stainless steel and hydroxyapatite implants in rat tibial bone. Biomaterials 16:1373-1380(1995).
4. M. Ben David, I. Katzir: Producing genetically engineered gonadotrophins – future replacement to natural gonadotrophins: profits, disadvantages and clinical use. Pharmacy update – The Israeli Pharmacy periodical 5:18-23 (1996). (in Hebrew)
5. I. Katzir: Using NMR spectroscopy in exploring tumors that are sensitive to the anti-neoplastic drug 5-fluorouracil. Pharmacy update – The Israeli Pharmacy periodical 6:7-10(1996). (in Hebrew)
6. I. Katzir: Treating asthma using salmeterol – a selective long acting beta-2-adreno-receptor agonist. Pharmacy update – The Israeli Pharmacy periodical 8:21-24(1997). (in Hebrew)
7. M. Shirav , J. Shani, I. Katzir , E. Ne’eman, D. Feigin, S. Brenner: Indoor and rock 222Rn levels in Israel - an integrated approach to radon risk assessment. Geological Survey of Israel – Current Research 12:34-40(2000). (in Hebrew)
8. I. Katzir, E. Berman, J. Shani, S. Chatterjee-Parti and W.Wolf: Enhancement of 5-fluoroutacil anabolism by methotrexate and by trimetrexate in two rat solid tumor models: Walker 256 adenocarcinoma and Novikoff hepatoma, evaluated by 19F-magnetic resonance spectroscopy. Cancer Invest. 18:20-7(2000).
9. I. Katzir, E. Berman, J. Shani and W.Wolf: Can 19F-2-FDG be used as a metabolic marker in 5-FU-Treated cancer patients? Pharmacol. Rev. Comm. 11:169-174 (2000).
10.R. Barzillai, J. Shani, I. Katzir, E. Shohami, V. Trembovler, E. Hirstakeva, M. Harari, A. Ingber: Serum vasoactive prostaglandins, TNFa and magnesium in hypertensive psoriatics undergoing climatotherapy at the dead sea. Pharmacol Rev. Comm. 11:131-142 (2000).
11.H. Halkin, I. Katzir, I. Kurman, J. Jan, B. Ben-Oz: Prevention of potential drug-drug interactions by computerized on-line prescription screening in community pharmacies and in medical practices, Clin. Pharmacol. Ther. 69:260-265(2001).
12.I. Katzir, J. Shani, K. Regev, D. Shavashov and P. Lazarovici: A Quantitative bioassay for nerve growth factor (NGF), Using PC12 Clones Expressing Different Levels of trkA Receptors. J. Mol. Neurosec. 18:251-264 (2002).
13.I. Katzir: Osteoporosis – how to avoid and how to treat. The Pharmaceutical Society of Israel Newsletter. (May 2003) (In Hebrew).
14.I. Katzir, J. Shani, D. Shavashov and P. Lazarovici: Establishment of PC12 cells tumor overexprssing trkA receptors cancer let. 200:177-185 (2003).
15. I. Katzir, J. Shani, G. Goshen, J. Sela2, E. Ninary, A.M. Dogonovski, S. Horie, K. Ikeda, Seiji Inoue, K. Hayashi and P. Lazarovici: Bioassay of Nerve Growth Factors (NGF’s) from snake venoms using a computerized morphometric method and PC12 cells overexpressing trkA receptor Toxicon 42:481-490 (2003).
16.R. Biberman, R. Neuman, I. Katzir and Y. Gerber: A randomized controlled trial of oral selsgiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addict. 98:1403-1407 (2003).
17.I. Katzir, R. Loebstein J. vesterman Landes, H. Halkin, Y. lomnicky. Database assesment of the effectiveness of brand versus generic rosiglitazone in patients with type 2 diabetes melitus. Value in Health 10:A255 (2007).
Abstracts
1. I. Katzir: Using magnetic resonance spectrosocopy for predicting the responsovness of a tumor to the drug 5-Fluorouracil. Congress of FIP - Clinical Pharmacology, Jerusalem, september 1996.
2. I. Katzir: Using magnetic resonance spectrosocopy for predicting the responsovness of a tumor to the drug 5-Fluorouracil. (abstract) Annual Meeting of The Israel Society for Physiology and Pharmacology Ma’ale Hachamisha, October 1996.
3. I. Katzir, J. Shani, E. Berman and W.Wolf: The use of 19F-NMR spectroscopy and 2-FDG for evaluating the response of 5-FU-sensitive tumor to 5-FU and to some of its chemotherapy modulators. Annual Meeting of The Israel Society for Physiology and Pharmacology Ma’ale Hachamisha, November 1997.
4. I. Katzir, J. Shani, D. Kaplan and P. Lazarovici. Characterization of PC12 Cells Overexpressing High Affinity “trkA”-Nerve Growth Factor (NGF) Receptors, and Their Use as a Bioassay for NGF. 50th Jubillee of The Medical School - Research Day Faculties of Medicine and Dentistry, The Hebrew University and the Hadassah Medical Organization. Ein Kerem campus, Jerusalem, 25th of May, 1999.
5. I. Katzir, J. Shani, D. Kaplan and P. Lazarovici. Characterization of PC12 Cells Overexpressing High Affinity “trkA”-Nerve Growth Factor (NGF) Receptors, and Their Use as a Bioassay for NGF. Annual Meeting of The Israel Society for Physiology and Pharmacology Ma’ale Hachamisha, October 1999.
6. B. Ben Oz, I. Katzir, J. Jan, I. Kurman and H.Halkin: On line computerized prevention of drug-drug interactions in primary care (presentation). The joint meeting of : 3rd Congress of The European Association for Clinical Pharmacology and Therapeutics (EACPT) and 4th Jerusalem Conference on Pharmaceutical Sciences and Clinical Pharmacology (JC4) 3-8 October 1999.
7. I. Katzir, J. Shani and P. Lazarovici: Bioassay for NGF Using PC12 clones expressing different levels of “trkA”- Receptors. NGF 2000 Montreal Canada, 26-30 May, 2000.
8. I. Katzir, E. Ninary, A.M. Dogonowski, G. Goshen J. Sela, J. Shani and P. Lazarovici: Quantitative comparison of four morphometric methods to evaluate NGF bioassay using PC12 cells overexpressing trkA receptors. NGF 2002, Modena Italy May 2002.
9. Y. Lomnitzky, I. Katzir, M. Dushinat, H. Halkin, Y. Shemer Population based assessment of the impact of substitution of Atorvastatin (A) by Simvastatin (S) on plasma lipid profile International Society of Technology Assessment in Health Care 19th Annual Meeting. Canmore, Canada, June 2003.
10. I. Katzir, H. Halkin, J. Shapiro, D. Kurnik, R. Loebstein, V. Shalev, E. Kokia Increase in Coumadin dosing and decrease in INR levels as a result of generic switch. Annual meeting of The Israel Association for medical information. Tel-Aviv, Israel, September 2003.
11. I. Katzir, H. Halkin, M. Dushenat, B. Silverman, V. Shalev, R. Loebstein, N. Friedman and Y. Lomnicky. Upper gastrointestinal tract outcomes in patients taking brand Vs. generic alendronate formulations. Annual meeting of the Israeli Society of Clinical Pharmacology, Tel Aviv, Israel, June 2006.
12. Y. Lomnicky, I. Katzir, R. Zarfati, E. Kokia. Prepering better Health for the patients. The 14th Annual meeting of the Israeli society for quality on medicine, Tamat Gan, Israel, May 2007.
13. T. Kenig, L. Vilekfort, I. Katzir, L. Valinsky, V. Rav Hon, M. Lapid, Y. Lomnicky. Improving Quality of diabetic patient healthcare using the pharmacist. The 14th Annual meeting of the Israeli society for quality on medicine, Ramat Gan, Israel, May 2007.
14. I. Katzir, R. Loebstein, J. Vasterman Landes, H. Halkin, Y. Lomnicky. Database assessment of the effectiveness of brand versus generic rosiglitazone in patients with type 2 diabetes mellitus. The 10th Annual meeting of ISPOR, Dublin, Irland, Octobr 2007.
מוסדות הארגון 
